adimmune.com.twCrawled Nov 10, 2026
Adimmune donated 500 doses of influenza vaccine to remote areas in the South-Link region and 400 doses to disadvantaged residents aged 19 to 49 in Nantou County, in partnership with Enimmune.
Adimmune added a second manufacturing line for a product partnered with Sanofi, completing Process Performance Qualification in one year and helping secure FDA approval within 20 months.
Adimmune displayed its new ready-to-use tetanus vaccine at CPHI Southeast Asia in Bangkok, generating interest from regional pharmaceutical companies.
Adimmune provides customized vaccine and biologics solutions for various scales, phases, and timelines as a global supplier.
Adimmune Corporation, a Taiwan-based human vaccine manufacturer, launches its first swine vaccine, expanding into the animal health sector. The company markets the product as a breakthrough in porcine immunization. The move follows industry coverage by porciNews.
The U.S. FDA is investigating **Addimune**, a Taiwanese vaccine manufacturer, following reports of mouse contamination in its facilities. The company states that mice were not housed in areas where medicines are produced. Regulatory scrutiny follows concerns over potential cross-contamination risks in pharmaceutical manufacturing.
Taiwan’s Food and Drug Administration (FDA) will inspect **Adimmune Corp** after a whistle-blower reported a suspected mouse infestation at the vaccine manufacturer. Health Minister Chiu Tai-yuan confirmed the inspection follows the allegation, though no details on contamination or operational impact were disclosed. The move comes amid heightened scrutiny of biopharmaceutical facilities in Taiwan.
Taiwan’s Centers for Disease Control (CDC) suspends a batch of Adimmune’s flu vaccine due to unusual discoloration. The agency assures the public that other batches remain unaffected and effective. Adimmune’s vaccines are widely used in Taiwan’s seasonal flu immunization programs.
Taiwan’s medical experts report rising enterovirus cases, including the first fatal infection in two years. The outbreak raises concerns among healthcare providers amid increasing hospitalizations. Authorities monitor the spread as seasonal enterovirus activity intensifies.
Adimmune Corp reports NT$236 million (US$8.52 million) in revenue for August, a 40% year-over-year increase driven by flu vaccine shipments to China. Chinese buyers this year have placed orders for 1.5 million doses, five times the volume from previous years. The company’s vaccine sales are fueling its financial growth amid strong demand.
Adimmune Corp begins phase I clinical trials for its COVID-19 vaccine candidate, marking Taiwan’s first FDA-approved trial for a domestically developed vaccine. The company submitted the application to the Taiwan Stock Exchange, signaling progress in local vaccine development amid the pandemic.
Adimmune Corp, a Taiwan-based vaccine manufacturer, announces plans to list on the stock exchange by March. The move marks a significant step for the company’s growth and public market presence in the pharmaceutical sector.